ALR Technologies announces conclusive preliminary results

SINGAPORE, 28 Feb. 12, 2022 (GLOBE NEWSWIRE) — ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced preliminary results from the non-inferiority study currently being performed on the GluCurve Pet CGM (GluCurve).

Using a chemical analyzer for the baseline, the GluCurve has so far performed on par with the leading veterinary blood glucose meter (BGM) and has met all of the accuracy requirements defined for human blood glucose meters in the ISO standard. :15197:2013.

“We are pleased with the accuracy of GluCurve compared to the leading companion animal BGM used by veterinarians. The platform provided valuable diagnostic information throughout the study that would not be available from the traditional glucose curve in the clinic. A significant advantage of GluCurve is that it is applied in minutes in the clinic and the animal is sent home. GluCurve records blood sugar levels every 3 minutes for up to 14 days while pet and owner go about their daily lives. This has many advantages over BGM, in which 5-7 data points are collected over 8-12 hours in a clinical setting. The process of housing a pet in the clinic and drawing blood every 2 hours causes stress that raises their blood sugar levels and is difficult for clinic staff to undertake. As part of the study, GluCurve was able to document the impact on glucose levels of the stressful clinical experience required for real-time BGM testing,” said Joe Stern, animal health manager at ALR Technologies.

Mr. Stern continues, “Data collected by GluCurve is processed and organized to help clinicians easily deliver optimal care. By comparing daily curves, the platform is able to show clinicians whether the animal is receiving insulin injections at the appropriate times, the animal’s eating habits, and a complete view of the animal’s blood sugar levels over time. time. Additionally, we received feedback from the lead study veterinarian confirming what other veterinarians and animal health companies have told us; they believe the GluCurve Pet CGM will become the standard of care for managing diabetic pets. We look forward to reviewing the final results with our potential pharmaceutical partner next month. »

About ALR Technologies
ALR Technologies is a data management company that has developed the ALRT Diabetes solution, a comprehensive approach to diabetes care that includes: an FDA-cleared, HIPAA-compliant diabetes management system that collects data directly from blood glucose meters and continuous blood glucose monitoring devices; a patent-pending A1C predictive algorithm to track treatment success between lab reports and an FDA-approved insulin dosage adjustment program. ALRT also offers an algorithm to provide support to prescribers for timely progress of medications other than insulin. The overall goal is to optimize drug treatments for diabetes to improve patient outcomes. The program tracks the performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes solution offers healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored in verifiable data.

Additionally, the Animal Health division identified an unmet need in diabetes care and developed GluCurve; a solution to help veterinarians determine the effectiveness of insulin and to help identify the appropriate dose and frequency of insulin administration for pets. Thus, offering the same optimization of diabetic drug therapies to pets as it does to humans.

On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. For more information about ALR Technologies Inc., visit Information regarding ALR Technologies SG Pte. ltd. can be found at


Ken Robulak (USA)
Phone: +1 (727) 736-3838

Anthony Ngai (Singapore)
Telephone: +65 3129 2924

Email: [email protected]


This press release contains certain “forward-looking statements” as defined by applicable securities laws. All information and statements contained herein that are not clearly historical in nature constitute forward-looking information, and the words “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect to”, “intend”, “plan”, “postulate”, “predict”, “will”, “may” or similar expressions suggesting future conditions or events or the negative form of these terms are generally intended identify forward-looking information. Forward-looking statements are necessarily based on a number of estimates and assumptions which, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ. and future events differ materially from those expressed or implied. by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements included in this press release are made as of the date hereof. ALR Technologies disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Previous Global Dog Clothing Market 2021 Product Scope – Weatherbeeta, RC Pet Products, Hurtta, Ruffwear – Business Ethics
Next How can the pet food industry deal with the supply chain impasse?